Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

Inclusion Criteria: * Males or females between 18 and 50 years, inclusive. * Good general health as determined by means of the screening procedure. * Available for the duration of the trial (44 weeks). * Willingness to participate in the study as evidenced by signing the informed consent document. Exclusion Criteria: * Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female). * Participant unwilling to use reliable contraception methods up until one month following the third immunization (if female and not surgically sterile, abstinent or at least 2 years post-menopausal). * Currently lactating and breast-feeding (if female). * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies. * Known or suspected immunodeficiency. * Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit). * Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing). * Laboratory evidence of hematologic disease (hemoglobin \<11.5 g/dl \[females\] or \<12.5 g/dl \[males\]; absolute leukocyte count \<3600/mm3 or \>10.7 x 103/mm3; absolute neutrophil count \[ANC\] \<1700/ mm3; absolute lymphocyte count \<700/mm3; or platelet count \<140,000/mm3). * Laboratory evidence …